Open AccessLong‐term survival and conditional survival of cancer patients in Japan using population‐based cancer registry data
Author(s) -
Ito Yuri,
Miyashiro Isao,
Ito Hidemi,
Hosono Satoyo,
Chihara Dai,
NakataYamada Kayo,
Nakayama Masashi,
Matsuzaka Masashi,
Hattori Masakazu,
Sugiyama Hiromi,
Oze Isao,
Tanaka Rina,
Nomura Etsuko,
Nishino Yoshikazu,
Matsuda Tomohiro,
Ioka Akiko,
Tsukuma Hideaki,
Nakayama Tomio
Publication year - 2014
Publication title -
cancer science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.035
H-Index - 141
eISSN - 1349-7006
pISSN - 1347-9032
DOI - 10.1111/cas.12525
Subject(s) - cancer , cancer registry , medicine , relative survival , population , thyroid cancer , survival analysis , survival rate , pancreatic cancer , oncology , demography , environmental health , sociology
Although we usually report 5‐year cancer survival using population‐based cancer registry data, nowadays many cancer patients survive longer and need to be followed‐up for more than 5 years. Long‐term cancer survival figures are scarce in Japan. Here we report 10‐year cancer survival and conditional survival using an established statistical approach. We received data on 1 387 489 cancer cases from six prefectural population‐based cancer registries in Japan, diagnosed between 1993 and 2009 and followed‐up for at least 5 years. We estimated the 10‐year relative survival of patients who were followed‐up between 2002 and 2006 using period analysis. Using this 10‐year survival, we also calculated the conditional 5‐year survival for cancer survivors who lived for some years after diagnosis. We reported 10‐year survival and conditional survival of 23 types of cancer for 15–99‐year‐old patients and four types of cancer for children (0–14 years old) and adolescent and young adults (15–29 years old) patients by sex. Variation in 10‐year cancer survival by site was wide, from 5% for pancreatic cancer to 95% for female thyroid cancer. Approximately 70–80% of children and adolescent and young adult cancer patients survived for more than 10 years. Conditional 5‐year survival for most cancer sites increased according to years, whereas those for liver cancer and multiple myeloma did not increase. We reported 10‐year cancer survival and conditional survival using population‐based cancer registries in Japan. It is important for patients and clinicians to report these relevant figures using population‐based data.